Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System

PeriTec Biosciences Ltd.1 site in 1 country45 target enrollmentNovember 2006

ConditionsVascular Disease, Peripheral

Overview

Phase: Early Phase 1
Intervention: Not specified
Conditions: Vascular Disease, Peripheral
Sponsor: PeriTec Biosciences Ltd.
Enrollment: 45
Locations: 1
Primary Endpoint: Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The occurrence of Peripheral Vascular Disease has been increasing which includes the large artery in the upper leg called Superficial Femoral Artery (SFA). The Peritoneal Lined Stent has been developed as a new method for treating narrowed area in the SFA. This research study will determine the safety and effectiveness of the Peritoneal Lined Stent in keeping th Superficial Femoral Artery open and allowing blood to flow in the leg.

Registry

clinicaltrials.gov

Start Date

November 2006

End Date

November 2010

Last Updated

18 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

PeriTec Biosciences Ltd.

Eligibility Criteria

Inclusion Criteria

•Patient with claudication or ischemic rest pain(Rutherford Categories 2-4)
•The angiogram will need to have been performed confirming superficial femoral artery short segment occlusion(\<5cm first two patients and \<10cm there on) or high grade(\>50%)stenosis
•Patient has a signed and dated informed consent
•Patient has a resting ABI \<0.9 or an abnormal exercise ABI if resting ABI is normal. Patients with incompressible arteries (ABI \>1.2) must have TBI \<0.8
•Life expectancy greater than one year
•The ability to comply with protocol follow up requirements and required testing
•Angiographic lesion requirements assessed at time of procedure
•Lesion of the superficial femoral artery with a short segment occlusion(\<5cm first two patients and \<10cm there on) or high grade (\>50%) stenosis
•Target lesion 1 cm below profunda/superficial femoral artery origin and 3cm above knee joint
•Angiographic evidence of a minimum of at least one tibial with continuous artery runoff to the ankle that does not require intervention

Exclusion Criteria

•Untreated iliac artery in-flow limiting lesion
•Significant proximal common femoral or superficial femoral artery disease above or below target lesion
•Any previously treated superficial femoral artery lesion
•Any previous stenting or surgery in the target vessel
•Femoral or popliteal aneurysm
•Non-Atherosclerotic disease resulting in occlusion (e.g. embolism, vasculitis,etc)
•Serum creatinine \>2.5 mg/dl
•Any previously known coagulation disorder, including hypercoagulability
•Severe medical co-morbidities or other medical condition (for example untreated coronary heart disease and congestive heart failure, severe chronic obstructive pulmonary disease, metastasis malignance, etc.)

Outcomes

Primary Outcomes

Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events

Time Frame: 30 Days

Secondary Outcomes

Primary Patency Primary Assisted Patency Secondary Patency Clinical Success Major Amputations Target Vessel Revascularization Target Lesion Revascularization(3 Months Intervals except for Target Lesion Revascularization at 12 months)